Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)

Anaptysbio's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $171000.0 for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0; the TTM value through Dec 2018 reached $171000.0, up 22.14%, while the annual FY2018 figure was $171000.0, 22.14% up from the prior year.
  • Non-Current Deffered Revenue reached $171000.0 in Q4 2018 per ANAB's latest filing, up from $162000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $171000.0 in Q4 2018 to a low of $128000.0 in Q2 2018.
  • Average Non-Current Deffered Revenue over 3 years is $151555.6, with a median of $154000.0 recorded in 2016.
  • The largest YoY upside for Non-Current Deffered Revenue was 22.14% in 2018 against a maximum downside of 23.81% in 2018.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $154000.0 in 2016, then fell by 9.09% to $140000.0 in 2017, then rose by 22.14% to $171000.0 in 2018.
  • Per Business Quant, the three most recent readings for ANAB's Non-Current Deffered Revenue are $171000.0 (Q4 2018), $162000.0 (Q3 2018), and $128000.0 (Q2 2018).